Debiopharm Announces Oncology Research Advancements at AACR 2022 for Novel Cancer Compounds and Drug Delivery Technologies
PR95421
LAUSANNE, Switzerland, April 11, 2022 /PRNewswire=KYODO JBN/ --
Pre-clinical & clinical exploratory poster presentations to highlight oncology
results with Debio 0123, xevinapant, and Multilink[TM] technology for antibody
drug conjugates
Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and
infectious disease focused biopharmaceutical company based in Switzerland,
today announced data releases on 3 investigational products including Debio
0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant
(IAP inhibitor), and 2 Multilink[TM] technology posters (antibody drug
conjugate linker) at the 2022 Annual American Association for Cancer Research
(AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the
focal point of the cancer research community to gather together and share
advances in oncology science. Debiopharm and their partners' poster
presentations represent scientific progress in the research of these compounds
leveraging novel modes of action and new delivery methods in development to
treat cancer types with high unmet needs.
"Scientific cancer research is evolving quickly, bringing us the insights
needed to better develop safer and more effective anti-tumor therapies. Our
ultimate vision is to translate these findings into meaningful outcomes for
patients in future clinical settings," explained Carolina Haefliger, Head of
Translational Medicine at Debiopharm.
AACR 2022 Poster Sessions
Compound Title Date and Time
N°
Debio 0123 The WEE1 inhibitor Debio 0123 Tue, April 12th,
#4894
enhances the efficacy of standard 9:00am-12:30pm
of care DNA Damaging agents in Section 5
lung cancer models
Multilink™ A novel antibody drug conjugate Mon, April 11th,
#4882
technology linker enabling production of ADCs 1:30-5:00pm
with high drug to antibody ratios and Section 21
fast payload release for improved
efficacy
Multilink™ The antibody-drug conjugate GENA-111 Mon, April 11th,
#1716
technology conjugated to auristatin F shows 1:30-5:00pm
(combined with therapeutic potency in BCAM Section 21
Genome & Co's positive epithelial cancer
Antibody)
xevinapant The IAP antagonist xevinapant in Tue, April 12th,
#603
(rights under Merck combination with high-dose cisplatin 1:30-5:00pm
KGaA, Darmstadt, chemoradiotherapy induces NF-kB and Section 33
Germany) apoptotic pathway biomarkers
in patients with high-risk, locally
advanced squamous cell carcinoma of
advanced the head and neck
About Debio 0123
Debio 0123[https://www.debiopharm.com/pipeline/debio-0123/] is an inhibitor of
WEE1 kinase, a key regulator of the G2/M and S phase checkpoints, activated in
response to DNA damage, allowing cells to repair their DNA before resuming
their cell cycle. WEE1 inhibition, particularly in combination with DNA
damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
In conjunction with abrogation of other checkpoints such as those of the G1
phase of the cell cycle, the compound pushes the cells through cycle without
DNA repair, promoting mitotic catastrophe and inducing apoptosis of cancer
cells.
About Multilink[TM]
Multilink[TM][https://www.debiopharm.com/manufacturing-science/technology-pipeli
ne/multilink/] is a new cleavable linker platform suited for multidrug
attachment and compatible with any conjugation technology to produce ADCs with
high DAR (drug-to-antibody ratio), allowing the loading of multiple payloads on
an antibody for an enhanced therapeutic effect. This highly effective and
well-tolerated linker platform is available for use of other specialty biotech
or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
About xevinapant
Xevinapant[https://www.debiopharm.com/pipeline/xevinapant/#head-and-neck-cancer]
, now exclusively licensed to Merck for product development and
commercialization, is a potential first-in-class potent, oral, small-molecule
inhibitor of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies,
xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving
them of one of their major resistance mechanisms to anticancer therapy.
Currently in phase III clinical research, in a randomized, placebo-controlled
phase II study, xevinapant has demonstrated preliminary evidence of efficacy in
combination with chemoradiotherapy (CRT) in patients with high-risk locally
advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a
clinically significant and sustained clinical activity and an acceptable safety
profile compared with CRT alone.
About Genome & Co.
Since its establishment in 2015, Genome and Company develops next waves of
innovative drugs including anti-cancer microbiome therapeutics and novel target
immune checkpoint inhibitors. Through continuing open innovations with global
external collaborations and strategic investments, the company has expanded its
microbiome pipeline into brain diseases and continues to pioneer the market in
becoming a fully integrated global healthcare group capable of research,
development and manufacturing of first-in-class pharmaceutical modalities
including microbiome. For more information, please refer to
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs
in oncology and infectious diseases. Bridging the gap between disruptive
discovery products and international patient reach, we identify high-potential
compounds and technologies for in-licensing, clinically demonstrate their
safety and efficacy and then select large pharmaceutical commercialization
partners to maximize patient access globally.
Visit us www.debiopharm.com/
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
- Picture is available at AP Images (http://www.apimages.com) -
Debiopharm Contact
Dawn Bonine – Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Source: Debiopharm International SA
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。